Gladman DD, Rigby WFC, Azevedo VF, et al. Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: OPAL BEYOND, a randomized, double-blind, placebo-controlled, phase 3 trial. EULAR 2017, OP0202.
Lage versus hoge dosis GC plus rituximab bij ANCA-vasculitis: resultaten na 2 jaar
jan 2024